# Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

> **NCT01540071** · PHASE2 · COMPLETED · sponsor: **Io Therapeutics** · enrollment: 38 (actual)

## Conditions studied

- Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** NRX 194204

## Key facts

- **NCT ID:** NCT01540071
- **Lead sponsor:** Io Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01540071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01540071, "Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01540071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*